CRISPR Therapeutics AG (CRSP) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $91.1 million.
- CRISPR Therapeutics AG's Accumulated Depreciation & Amortization rose 2598.52% to $91.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $91.1 million, marking a year-over-year increase of 2598.52%. This contributed to the annual value of $91.1 million for FY2025, which is 2598.52% up from last year.
- CRISPR Therapeutics AG's Accumulated Depreciation & Amortization amounted to $91.1 million in Q4 2025, which was up 2598.52% from $85.6 million recorded in Q3 2025.
- In the past 5 years, CRISPR Therapeutics AG's Accumulated Depreciation & Amortization ranged from a high of $91.1 million in Q4 2025 and a low of $23.9 million during Q1 2021
- For the 5-year period, CRISPR Therapeutics AG's Accumulated Depreciation & Amortization averaged around $53.0 million, with its median value being $49.8 million (2022).
- Examining YoY changes over the last 5 years, CRISPR Therapeutics AG's Accumulated Depreciation & Amortization showed a top increase of 8566.65% in 2022 and a maximum decrease of 1479.92% in 2022.
- Quarter analysis of 5 years shows CRISPR Therapeutics AG's Accumulated Depreciation & Amortization stood at $37.8 million in 2021, then decreased by 10.51% to $33.8 million in 2022, then surged by 57.94% to $53.4 million in 2023, then skyrocketed by 35.26% to $72.3 million in 2024, then grew by 25.99% to $91.1 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $91.1 million for Q4 2025, versus $85.6 million for Q3 2025 and $81.6 million for Q2 2025.